Valuation: TTY Biopharm Company Limited

Market Cap 19.62B 616M 547M 511M 466M 878M 59.21B 886M 6.18B 2.39B 30.27B 2.31B 2.26B 97.14B P/E 2026 *
-
P/E 2027 * -
Enterprise Value 19.62B 616M 547M 511M 466M 878M 59.21B 886M 6.18B 2.39B 30.27B 2.31B 2.26B 97.14B EV / Sales 2026 *
2.78x
EV / Sales 2027 * -
Free-Float
78.69%
Yield 2026 *
-
Yield 2027 * -
1 day+0.51%
1 week+0.77%
Current month+0.51%
1 month+2.07%
3 months+1.28%
6 months+7.20%
Current year-3.19%
1 week 78
Extreme 78
78.9
1 month 76.3
Extreme 76.3
79.3
Current year 71.6
Extreme 71.6
87
1 year 71.6
Extreme 71.6
87
3 years 66.2
Extreme 66.2
87
5 years 66.2
Extreme 66.2
88.5
10 years 54.2
Extreme 54.2
135.5
Manager TitleAgeSince
Chief Executive Officer - 2022-04-17
Director of Finance/CFO - 2015-12-30
Compliance Officer - 2022-04-17
Director TitleAgeSince
Director/Board Member - 1995-07-23
Director/Board Member - 2016-06-23
Director/Board Member 70 2016-06-23
Change 5-day change 1-year change 3-year change Capi.($)
+0.51%+0.77%+0.25%+2.20% 616M
-0.61%-3.43%+36.07%+117.61% 1,019B
-1.02%-5.60%+35.72%+64.82% 617B
+1.11%-0.58%+12.36%+78.27% 464B
+0.34%-3.01%+61.79%+41.79% 356B
-0.95%-4.05%+20.54%+40.33% 333B
-1.46%-2.89%+10.57%+26.54% 267B
-1.35%-5.43%-6.17%+8.82% 244B
-1.04%-2.79%+35.30%+54.42% 218B
-1.87%-4.10%+28.44%+97.54% 179B
Average -0.63%-2.98%+23.49%+53.23% 369.78B
Weighted average by Cap. -0.60%-3.32%+29.07%+71.14%

Financials

2026 *2027 *
Net sales 7.05B 221M 197M 183M 167M 315M 21.26B 318M 2.22B 860M 10.87B 830M 812M 34.89B -
Net income - -
Net Debt - -
Logo TTY Biopharm Company Limited
TTY Biopharm Co Ltd is a Taiwan-based company mainly engaged in the research, development, manufacture and sale of pharmaceutical preparations. The Company mainly operates through six business segments including Cancer Drug segment, Healthcare segment, Anti-Infective Drug segment, Domestic Cardiovascular and Gastrointestinal Drug segment, Mainland Medical Drug segment and the Other segment. The main products include oncology medicines, anti-infective medicines and health care medicines. Oncology medicines are mainly anti-cancer and auxiliary drugs. Anti-infective medicines are mainly back-line antimicrobial agents and influenza vaccines. Medical and health care medicines are mainly gastrointestinal health care, bone health care, metabolic health care, infection treatment drugs. The Company distributes its products in domestic and overseas markets.
Employees
-
Date Price Change Volume
26-10-02 NT$78.90 +0.51% 314,185
26-10-01 NT$78.50 0.00% 449,424
26-09-30 NT$78.50 -0.38% 543,776
26-09-29 NT$78.80 +0.64% 294,114
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
78.90TWD
Average target price
92.00TWD
Spread / Average Target
+16.60%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. 4105 Stock